Published in Pharma Investments, Ventures and Law Weekly, December 26th, 2004
The company reported a net loss of $2,428,000, or $0.16 per share, for the third quarter, as compared to net loss of $2,206,000, or $0.17 per share, for the corresponding quarter in 2003. The net loss for the 9-month period ended September 30, 2004, was $7,332,000, or $0.49 per share, compared with a net loss of $4,301,000, or $0.32 per share for the corresponding period in 2003.
The results in 2003 include miscellaneous income of $2.3 million resulting from the settlement of a dispute related to the supply of Aphthasol.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.